Start-up
ICOVELL
ICOVELL reveals the mechanical ability of red blood cells to travel in the blood microcirculation.
ICOVELL's dynared platform provides a mechanical marker that characterizes the deformability of large populations of red blood cells based on single cell measurements, and allows for the clinical monitoring of patients with sickle cell disease.
OPTIPUS
OPTIPUS offers high-efficiency photovoltaic technology with the potential for aesthetic integration into the nomadic objects of our everyday lives
OPTIPUS' technological innovation is based on the manufacture of high performance conformal organic photovoltaic modules with specific patterns, designs and colors. This allows them to be fully integrated into a product, so that the module becomes either invisible (discreet integration) or highlighted by its colors, while displaying its functionality.
SILON THERAPEUTICS
SILON THERAPEUTICS builds on 30 years of groundbreaking oncology cutting-edge research in oncology at the interface of biology and chemistry, led by Dr. Palma Rocchi's “RNAnoTher” lab (Inserm ERLU1326).
This pioneering work identified the critical role of the Hsp27 signaling pathway in driving treatment resistance in prostate cancer. As a result, the team developed an antisense oligonucleotide (ASO) targeting Hsp27 mRNA (OGX-427, Apatorsen), a patented innovation from the University of British Columbia, licensed to Canadian company Oncogenex. In collaboration with Ionis, Apatorsen has been evaluated in Phase II clinical trials for prostate, lung, bladder, and ovarian cancers.
SILON TX is focused on enhancing the stability, bioavailability, and delivery of Apatorsen by creating versatile, modular nano-objects with its proprietary nucleolipid conjugate technology. Our mission is to demonstrate the superior therapeutic potential of these intelligent nano-objects and to develop a breakthrough drug candidate for advanced prostate cancer. Our cutting-edge approach provides a dual benefit: more effective treatment with reduced toxicity.
With its precision and rapid production capabilities, this technology has the potential to revolutionize the treatment of advanced prostate cancer by delivering personalized, targeted care.